Trospium
Sanctura (trospium) is a small molecule pharmaceutical. Trospium was first approved as Sanctura on 2004-05-28. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| trospium chloride | ANDA | 2023-05-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| overactive urinary bladder | EFO_1000781 | D053201 | N32.81 |
| urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03D: Antispasmodics in combination with analgesics
— A03DA: Synthetic anticholinergic agents in combination with analgesics
— A03DA06: Trospium and analgesics
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BD: Drugs for urinary frequency and incontinence
— G04BD09: Trospium
HCPCS
No data
Clinical
Clinical Trials
1036 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 23 | 43 | 6 | 1 | 5 | 69 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 12 | 5 | 22 | 1 | 3 | 43 |
| Postoperative pain | D010149 | G89.18 | 2 | 5 | 6 | 10 | 6 | 28 | |
| Neoplasms | D009369 | C80 | 13 | 9 | 3 | 1 | 3 | 25 | |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 4 | 7 | 4 | 3 | 1 | 18 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 4 | 1 | 5 | 6 | 1 | 16 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 3 | 3 | 6 | 2 | 15 |
| Hyperphosphatemia | D054559 | HP_0002905 | — | 1 | 4 | 3 | 6 | 13 | |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | 3 | 3 | 3 | 3 | 12 |
| Malaria | D008288 | EFO_0001068 | B54 | 6 | 1 | — | 2 | — | 8 |
Show 79 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 51 | 97 | 8 | — | 14 | 149 | |
| Leukemia | D007938 | C95 | 37 | 83 | 13 | — | 10 | 122 | |
| Lymphoma | D008223 | C85.9 | 27 | 61 | 4 | — | 15 | 96 | |
| Myeloid leukemia acute | D015470 | C92.0 | 42 | 58 | 5 | — | 5 | 95 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 29 | 43 | 4 | — | 4 | 72 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 20 | 36 | 1 | — | 5 | 54 | |
| Multiple myeloma | D009101 | C90.0 | 19 | 31 | 2 | — | 6 | 52 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 10 | 33 | 2 | — | 3 | 43 | |
| Hodgkin disease | D006689 | C81 | 13 | 26 | 4 | — | 4 | 41 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 12 | 21 | 2 | — | 3 | 33 |
Show 93 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | 14 | 28 | — | — | 6 | 44 | ||
| Melanoma | D008545 | 12 | 17 | — | — | — | 27 | ||
| Healthy volunteers/patients | — | 18 | 1 | — | — | 4 | 22 | ||
| Burkitt lymphoma | D002051 | C83.7 | 6 | 14 | — | — | 3 | 21 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | 7 | 11 | — | — | 4 | 20 | |
| Primary myelofibrosis | D055728 | D47.4 | 5 | 11 | — | — | 2 | 18 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 5 | 13 | — | — | 3 | 18 | |
| Large-cell lymphoma immunoblastic | D016400 | 5 | 11 | — | — | 3 | 17 | ||
| Lymphomatoid granulomatosis | D008230 | C83.8 | 4 | 11 | — | — | 3 | 16 | |
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | 4 | 10 | — | — | 3 | 15 |
Show 118 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | 1 | 3 |
| Plasmacytoma | D010954 | C90.3 | 1 | — | — | — | 1 | 2 | |
| Rickets | D012279 | EFO_0005583 | E55.0 | 1 | — | — | — | 1 | 2 |
| Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
| Gram-positive bacterial infections | D016908 | 2 | — | — | — | — | 2 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | — | — | — | — | 2 |
| Dengue | D003715 | A90 | 2 | — | — | — | — | 2 | |
| Depression | D003863 | F33.9 | 2 | — | — | — | — | 2 | |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | — | — | — | — | 1 |
| Plantar fasciitis | D036981 | EFO_1001909 | M72.2 | 1 | — | — | — | — | 1 |
Show 35 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sars-cov-2 | D000086402 | — | — | — | — | 2 | 2 | ||
| Sinus floor augmentation | D059546 | — | — | — | — | 2 | 2 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Papillomaviridae | D027383 | — | — | — | — | 1 | 1 | ||
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | — | 1 | 1 |
| Sexual behavior | D012725 | — | — | — | — | 1 | 1 | ||
| Hypertrophic cicatrix | D017439 | L91.0 | — | — | — | — | 1 | 1 | |
| Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
| Keloid | D007627 | EFO_0004212 | L91.0 | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | P22 | — | — | — | — | 1 | 1 |
Show 41 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TROSPIUM |
| INN | trospium chloride |
| Description | Trospium chloride is an organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder. It has a role as a muscarinic antagonist and an antispasmodic drug. It is an organic chloride salt and a quaternary ammonium salt. It contains a trospium. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 10405-02-4 |
| RxCUI | 38891 |
| ChEMBL ID | CHEMBL1888176 |
| ChEBI ID | — |
| PubChem CID | 5284631 |
| DrugBank | DB00209 |
| UNII ID | 1E6682427E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,064 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more